Medexus Pharmaceuticals Inc. — News

Fiscal Q1 2027 includes product-level net revenue from GRAFAPEX™ (treosulfan) for Injection of $4.9 million relative to $3.2 million of GRAFAPEX personnel and infrastructure investments Commercial traction observed to date reinforces Medexus confidence in the growth trajectory of GRAFAPEX Management to host conference call at 8:00 AM Eastern time on Tuesday, August 11, 2026 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 10, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's first fiscal quarter ended June 30, 2026 (the Company's fiscal Q1 2027). All dollar amounts in this news release are in US dollars unless specified otherwise.

newsfilecorp.com - 2026-08-10 17:30:00

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - July 30, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Tuesday, August 11, 2026 to discuss Medexus's results for its first fiscal quarter ended June 30, 2026. Medexus expects to file its financial statements and MD&A after markets close on August 10, 2026.

newsfilecorp.com - 2026-07-30 17:30:00

Management to host conference call at 8:00 AM Eastern time on Friday, June 26, 2026 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 25, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's fourth fiscal quarter and fiscal year ended March 31, 2026 (the company's fiscal Q4 2026 and fiscal year 2026). All dollar amounts in this news release are in US dollars unless specified otherwise.

newsfilecorp.com - 2026-06-25 18:00:00

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 16, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Friday, June 26, 2026 to discuss Medexus's results for its fourth fiscal quarter and fiscal year ended March 31, 2026. Medexus expects to file its financial statements and MD&A after markets close on June 25, 2026.

newsfilecorp.com - 2026-06-16 17:30:00

UM171 Cell Therapy is conditionally approved in Europe as Zemcelpro® (dorocubicel) Securing Canadian rights to a proprietary advanced clinical-stage product candidate developed in Canada adds to Medexus's medium-term product pipeline and helps build a North American allo-HSCT franchise Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 9, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the company has secured exclusive Canadian rights to commercialize UM171 Cell Therapy, a proprietary advanced clinical stage investigational drug product that recently received conditional marketing authorization in Europe from the European Commission (or EC) as Zemcelpro® (dorocubicel), in a license and supply deal with ExCellThera, a blood stem cell expansion and metabolic fitness company, and Cordex Biologics, its wholly owned subsidiary. Zemcelpro® is a novel personalized cryopreserved hematopoietic stem cell transplantation product containing two components, namely UM171-expanded CD34+ cells (dorocubicel) and unexpanded CD34- cells, each derived from the same cord blood unit.

newsfilecorp.com - 2026-06-09 17:30:00